title: [The relationship between retinoic acid receptor-β expression and chemotherapy response in esophageal squamous cell carcinoma].
abstract: OBJECTIVE
  To observe the relationship between expression of retinoic acid receptor-β(RAR-β) in esophageal squamous cell carcinoma (ESCC) and chemotherapy response.
  
  
  METHODS
  Fifty-two cases advanced ESCC patients treated by DDP and 5-FU, DDP 80 mg/m(2), divided into 5 days; 5-FU 375 mg/m(2), d1-5. Immunohistochemistry was used to examine the expression of RAR-β in ESCC. Fifty cases normal esophageal tissue were used as controls.
  
  
  RESULTS
  RAR-β immunoreactivity was recognized in both cytoplasm and nucleus, RAR-β positive rate was lower in ESCC compared with normal tissue (61.5% vs 92%, P < 0.05). The 52 cases ESCC patients were treated 228 chemotherapy cycles, the overall response rate (OR) was 71.2%. The OR in RAR-β positive patients was 84.4% (27/32), significant higher than RAR-β negative patients 50.0% (10/20) (P < 0.05). The time-to-progression (TTP) for RAR-β positive patients was 5.9 months, the median survival period was 12.1 months, 2 years survival rate was 56.7%; whereas TTP for RAR-β negative patients was 2.1 months, the median survival period was 5.8 months, 2 years survival rate was 32.9%. There was significant difference between the 2 groups (P < 0.05).
  
  
  CONCLUSIONS
  RAR-β protein expression by immunohistochemistry may be a useful indicator to predict the chemotherapy response and clinical outcome for ESCC, meanwhile it may be an avenue for target therapy.
authors.affiliation: Department of Oncology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
authors.forename: Tai-ying
authors.initials: TY
authors.lastname: Lu
authors.forename: Wen-bin
authors.initials: WB
authors.lastname: Li
authors.forename: Xin
authors.initials: X
authors.lastname: Li
authors.forename: Liu-xing
authors.initials: LX
authors.lastname: Wang
authors.forename: Rui-lin
authors.initials: RL
authors.lastname: Wang
authors.forename: Lan
authors.initials: L
authors.lastname: Zhang
authors.forename: Shi-xin
authors.initials: SX
authors.lastname: Lu
authors.forename: Qing-xia
authors.initials: QX
authors.lastname: Fan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000378:metabolism*; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018168:Receptors, Retinoic Acid / Q000378:metabolism*
chemical_list: D018168:Receptors, Retinoic Acid; C082925:retinoic acid receptor beta